-
2023-507010-27-00
5
Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cu
-
2024-514848-88-00
4
Folliculitis decalvans
-
2024-516849-39-01
5
antibiotic therapy in Sepsis
-
2024-518251-31-00
5
patients hospitalized for a septic shock with hypercontractlity
-
2024-520089-70-00
5
Cutaneous lupus erythematosus
-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-521093-34-00
5
rare disease
-
2025-522193-37-00
5
Septic arthritis
-
2025-522655-26-00
4
METAREM:Patients with advanced cancer, as defined as unresectable loca
-
2025-522790-10-00
4
Non Small Cell Lung Cancer
-
2025-523149-80-00
10
Adult patients admitted to the ICU and receiving unplanned invasive me
-
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-523522-41-00
10
Extensive-Stage Small Cell Lung Cancer
-
2025-524297-42-00
5
CLTI defined as Rutherford category 4 or 5
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-503920-14-00
5
2024-01-02
Non-Small Cell Lung Cancer (NSCLC)
-
2022-500966-82-00
5
2020-03-11
Resectable locally advanced squamous cell carcinoma (SCC) of the esoph
-
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-